Risitano Angela, Toni Danilo
Department of Human Neurosciences, "La Sapienza" University, Rome, Italy.
Eur Heart J Suppl. 2020 Nov 18;22(Suppl L):L155-L159. doi: 10.1093/eurheartj/suaa157. eCollection 2020 Nov.
Ischaemic stroke is the second leading cause of mortality and disability in the western world. Revascularization interventions are the cornerstone of the acute treatment of this pathology and must be administered as soon as possible after the patient's arrival. They consist of intravenous thrombolysis (IVT) with alteplase, recommended by the guidelines within 4.5 h of the onset of symptoms, and endovascular treatment, recommended within 6 h of the onset of symptoms. The individualized patient selection based on the extent of the mismatch between the penumbra and the ischaemic core allowed to overcome the limits imposed by the rigid time windows, defining a benefit of mechanical revascularization therapies up to 24 h from the theoretical onset of symptoms (last time the patient was known to be well) and up to 9 h for IVT since the theoretical onset of symptoms (last time the patient was known to be well). Advanced neuroimaging methods with perfusion studies are a fundamental tool in patient selection. Their spread in the territory, together with a greater availability of neurovascular treatment units are desirable to ensure a fair delivery of treatment to all patients with ischaemic stroke.
缺血性中风是西方世界导致死亡和残疾的第二大主要原因。血管再通干预是这种疾病急性治疗的基石,必须在患者到达后尽快进行。这些干预措施包括静脉注射阿替普酶进行溶栓治疗(IVT),指南建议在症状发作后4.5小时内进行,以及血管内治疗,建议在症状发作后6小时内进行。基于半暗带和缺血核心之间不匹配程度的个体化患者选择,克服了严格时间窗所带来的限制,确定了从理论症状发作(患者最后一次状态良好的时间)起24小时内机械血管再通治疗的益处,以及从理论症状发作(患者最后一次状态良好的时间)起9小时内IVT的益处。带有灌注研究的先进神经成像方法是患者选择的基本工具。它们在该领域的普及,以及神经血管治疗单元的更多可及性,对于确保向所有缺血性中风患者公平提供治疗是可取的。